11494 Sorrento Valley Road
435 articles with Inovio
Inovio Pharmaceuticals, Inc. announced that Joseph Kim, President and CEO, will present an Inovio overview and business update at two upcoming investor conferences
The collaboration will focus on Inovio’s VGX-3100, which stimulates a specific immune response to HPV-16 and HPV-18, targeting the infection and causing destruction of precancerous cells.
Inovio and QIAGEN Establish Collaboration to Develop Diagnostic Test for VGX-3100, Inovio's Novel Immunotherapy Targeting Advanced Cervical Pre-Cancer
Liquid biopsy-based Precision Medicine test to guide patient selection for Inovio's VGX-3100
Inovio Presents Cancer Killing Data of Its Transformative DNA-Encoded Bi-specific T Cell Engagers (dBiTEs) at AACR
Data demonstrates tumor-clearing ability of Inovio's dBiTE technology in preclinical cancer model
Inovio Completes Enrollment Ahead of Schedule In Immuno-Oncology Study for Glioblastoma (GBM) with INO-5401 in Combination with Regeneron's PD-1 Inhibitor
Inovio Pharmaceuticals, Inc. announced that its Phase 1/2 immuno-oncology trial in patients with newly diagnosed glioblastoma has completed its enrollment three months ahead of schedule.
Inovio Pharmaceuticals, Inc. announced the appointment of Dr. Ann C. Miller to its Board of Directors.
Inovio Pharmaceuticals, Inc., a late-stage biotechnology company focused on the development and commercialization of DNA immunotherapies targeted against cancers and infectious diseases, reported financial results for the fourth quarter and year ended December 31, 2018.
Inovio Pharmaceuticals to Announce Fourth Quarter and Full Year 2018 Financial Results and Host Conference Call on March 12, 2019
Inovio Pharmaceuticals, Inc. announced that 2018 fourth quarter and full year financial results will be released after the market close on March 12, 2019.
Geneos Therapeutics Secures $10.5 Million in Series A Financing to Develop the Next Generation of Neoantigen-Targeting Cancer Immunotherapies
Geneos has Licensed Immunotherapy Platform from Inovio Pharmaceuticals for Developing Personalized Cancer Treatments
Inovio Announces First Subject Dosed with its DNA-Encoded Monoclonal Antibody (dMAb™) In First-Ever Human Trial
Inovio Pharmaceuticals, Inc. in collaboration with The Wistar Institute and the University of Pennsylvania announced that the first subject was dosed as part of the first-ever human study of Inovio's DNA-encoded monoclonal antibody technology.
Inovio Pharmaceuticals, Inc. announced the pricing of its offering of $65.0 million aggregate principal amount of 6.50% convertible senior notes due 2024.
First Human dMAb Study Will Target Zika Infection
Companies Continue to Take Aim at Glioblastoma, a Cancer Highlighted by the Death of Sen. John Mc...
8/27/2018McCain died Saturday after deciding to discontinue treatment for brain cancer. He approached the end of his life in the same manner in which he approached me that day in Raleigh – with the strength of character.
In the biotech world, only 7 to 9 percent of companies have women as their chief executives. Antiva BioSciences is a good example of how this problem is perpetuated.
8/15/2018On a dollar-for-dollar basis, vaccines have probably had a greater positive effect on global health than any other medical advancement, except possibly antibiotics. Yet as a whole, it’s an area that pharma companies tend to not spend a lot of resources on. But there are still many companies that ...
Ebola cases, as well as cases of other significantly lethal viral outbreaks that have occurred has spurred researchers to focus on the development of antivirals that can treat the illnesses.
The Loncar Cancer Immunotherapy Index has reduced the number of immunotherapy-focused companies from 30 to 25 and also swapped out a number of stocks as part of an effort to strengthen the index’s liquidity profile and ensure the holdings hold equal weight.
The 2017/2018 influenza season was considered one of the worst, made more so by the ineffectiveness of the season’s flu vaccine. The FDA is focusing partially on simply determining why this year’s flu vaccine missed the mark.
Inovio and The Wistar Institute Receive More Than $4.6M in R&D Funding to Advance Vaccines Against Tuberculosis & Malaria
The grants were from the Bill & Melinda Gates Foundation and the (NIH.
Inovio Pharmaceuticals' Published Universal Flu Vaccine Data Demonstrates Protective Responses Against All Major, Lethal H1N1 Influenza Viruses From the Last 100 Years in Animal Models
The flu vaccine also affords 100% protection against lethal challenge in the gold standard ferret model, demonstrating the functionality of such broad protective immune responses.